1. A single domain antibody capable of specifically binding to an epitope of a human and/or mouse complement factor selected from the group consisting of C1q, C4 and/or the proteolytic derivative C4b, C3 and/or the proteolytic derivative C3b.

2. The single domain antibody according to claim 1, wherein at least a part of said epitope is situated in the region of human C1q identified by any one of SEQ ID NO: 3-5.

3. The single domain antibody according to claim 1, wherein at least a part said epitope is situated in the region of human C4A and/or Human C4B identified by any one of SEQ ID NO: 6-8 and 80-82.

4. The single domain antibody according to claim 1, wherein at least a part of said epitope is situated in the region of human and/or mouse C3 identified by any one of SEQ ID NO: 1-2 and 74-75.

5. The single domain antibody according to claim 1, wherein said antibody is capable of modulating the activity of the complement system.

6. (canceled)

7. (canceled)

8. The single domain antibody according to claim 1, wherein said antibody is coupled to another single domain antibody, antibody or other binding moiety yielding a bispecific antibody, which consists of or comprises

a. the single domain antibody as defined in claim 1 and

b. one single domain antibody or other binding moiety capable of specifically binding to an epitope of a second target.

9. The single domain antibody according to claim 8, wherein said second target is a cancer-specific marker, a pathogenic marker, a tissue-specific marker or an organ-specific marker.

10. (canceled)

11. The single domain antibody according to claim 1, wherein said antibody comprises a CDR, which is at least 75% identical to a CDR selected from the group consisting of SEQ ID Nos: 10-12, 14-16, 18-20, 22-24, 26-28, 30-32, 34-36, 38-40, 42-44, 46-48, 50-52, 54-56, 58-60, 62-64, 67-69 and 71-73.

12. The single domain antibody according to claim 1, wherein said antibody is capable of specifically binding to an epitope of the human C3b and/or is capable of inhibiting assembly of the C3bBb convertase and/or is capable of inhibiting C3 cleavage.

13. The single domain antibody according to claim 1, wherein said antibody is capable of binding C3 and C3b and is selected from the group consisting of D121 and DI62.

14. The single domain antibody according to claim 11, wherein said antibody is capable of specifically binding C3b and not C3 and is selected from the group consisting of EWE-hC3Nb1 and IgG-Fc-hC3Nb1.

15. (canceled)

16. (canceled)

17. The single domain antibody according to claim 1, wherein the said antibody binds said complement factor with an affinity corresponding to a KD of about 10^{-6} M or less.

18. (canceled)

19. (canceled)

20. (canceled)

21. A method of treating a disorder associated with complement activation, said method comprising administering a therapeutically effective amount of a single domain antibody according to claim 1 to a subject in need thereof.

22. The method according to claim 21, wherein said disorder is selected from the group consisting of ocular diseases, neurological diseases, autoimmune and inflammatory disorders, cancers and infectious diseases.

23. The method according to claim 21, wherein said single domain antibody is a bispecific antibody comprising a single domain antibody capable of specifically binding to an epitope of a cancer-specific marker, a pathogenic marker, a tissue-specific marker or an organ-specific marker.

24. The method of claim 23, wherein said bispecific antibody is capable of recruiting complement factors to a specific cancer, pathogen, tissue or organ, and is capable of activating the complement system at the site of said cancer, pathogen, tissue or organ.

25. A method of modulating the activity of the complement system, said method comprising

a) providing a composition comprising a human complement factor selected from the group consisting of C1q, C4 and/or the proteolytic derivative C4b, C3 and/or the proteolytic derivatives C3b,

b) contacting said composition with a single domain antibody according to claim 1.

26. The method according to claim 23, wherein said composition is serum, plasma, blood or cerebrospinal fluid.

27. The method according to any one of claims 21 and 2626, wherein said method is an in vitro method or an in vivo method.

28. (canceled)

29. The method according to claim 25, wherein the method comprises the steps of administering to an individual in need thereof a therapeutically effective amount of said antibody.

30-34. (canceled)

* * * * *